In contrast with cell therapy approaches based on the transplantation of single cells, the C-Stem™ technology generates 3D neural microtissues containing mature dopaminergic neurons.
Since 2018, preclinical studies demonstrated robust in vivo effects and safety profile, with fast and complete motor function recovery.
Aiming at a first-in-human trial in 2025, TreeFrog is now moving forward with regulatory toxicology studies and is transferring the GMP C-Stem™ platform to a CDMO to manufactur clinical-grade batches.